Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023
Narayana Hrudayalaya has reported total income of Rs. 1323.64 crores during the period ended September 30, 2023
Yesafili, received marketing authorization approval from the European Commission for the European Union
Subscribe To Our Newsletter & Stay Updated
